Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis

Qu, Haixia; Zhao, Liping; Zhan, Shuai; Geng, Chang‐Xin; Xu, Lin; Xin, Yongning; Jiang, Xiangjun

doi:10.21037/jtd.2016.11.01

Cited by 42 publications

(38 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Qu et al [ 97 ] performed a meta-analysis of the prognostic significance of PD-L1 expression in ESCC patients. The study showed that overexpression of PD-L1 tended to be associated with short OS in ESCC; however, the difference did not reach statistical significance ( P = 0.07).…”

Section: Resultsmentioning

confidence: 99%

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Wang

Chen

et al. 2017

Chin J Cancer

View full text Add to dashboard Cite

BackgroundEsophageal squamous cell carcinoma (ESCC) is an aggressive malignancy, with a high incidence and poor prognosis. In the past several decades, hundreds of proteins have been reported to be associated with the prognosis of ESCC, but none has been widely accepted to guide clinical care. This study aimed to identify proteins with great potential for predicting prognosis of ESCC.MethodsWe conducted a systematic review on immunohistochemical (IHC) prognostic markers of ESCC according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Literature related to IHC prognostic markers of ESCC were searched from PubMed, Embase, Web of Science, and Cochrane Library until January 30th, 2017. The risk of bias of these original studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool.ResultsWe identified 11 emerging IHC markers with reproducible results, including eight markers [epidermal growth factor receptor (EGFR), Cyclin D1, vascular endothelial growth factor (VEGF), Survivin, Podoplanin, Fascin, phosphorylated mammalian target of rapamycin (p-mTOR), and pyruvate kinase M2 (PKM2)] indicating unfavorable prognosis and 3 markers (P27, P16, and E-cadherin) indicating favorable prognosis of ESCC.ConclusionStrong evidence supports that these 11 emerging IHC markers or their combinations may be useful in predicting prognosis and aiding personalized therapy decision-making for ESCC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s40880-017-0232-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Wang

Chen

et al. 2017

Chin J Cancer

View full text Add to dashboard Cite

show abstract

“…[ 36 – 40 ] However, inconsistent results have been reported in esophageal squamous cell cancer, and head and neck cancer, with no association between PD-L1 expression and survival. [ 41 , 42 ]…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

et al. 2018

View full text Add to dashboard Cite

Background:Programmed cell death ligand 1 (PD-L1) overexpression has been reported to be associated with poor prognosis in several human cancers. However, studies on the prognostic value of PD-L1 expression in ovarian carcinoma (OC) remain controversial. This meta-analysis aimed to evaluate comprehensively the prognostic value of PD-L1 in OC.Methods:Electronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched up until March 28, 2018. Hazard ratio (HR), along with 95% confidence interval (CI), was used to analyze the included outcomes.Results:A total of 10 studies with 1179 OC patients were included in this meta-analysis. There was no significant correlation between PD-L1 expression and overall survival (OS) (HR 1.23, 95% CI 0.85–1.79) and progression-free survival (PFS) (HR 0.88, 95% CI 0.52–1.47) of OC patients. However, the subgroup analysis suggested that positive PD-L1 expression was significantly associated with poor OS (HR 1.66, 95% CI 1.08–2.55) and PFS (HR 2.17, 95% CI 1.31–3.61) among OC patients from Asian countries. Increased PD-L1 expression was also a favorable factor for OS (HR 0.73, 95% CI 0.53–0.99) and PFS (HR 0.58, 95% CI 0.45–0.75) in OC patients from non-Asian regions. No evidence of publication bias was detected by the Egger linear regression test and Begg funnel plot. Sensitivity analyses suggested that the results of this meta-analysis were robust.Conclusions:The results indicated that PD-L1 expression may be a negative predictor for prognosis of OC patients from Asian countries, and a good predictor for favorable prognosis of OC patients from non-Asian countries. PD-L1 expression has potential to be a prognostic biomarker to guide clinicians for the selection of individuals who may get clinical benefit from anti-PD-1/PD-L1 immunotherapy. Prospective clinical studies are needed to support these findings.

show abstract

“…Previous studies have been conducted to evaluate the association of clinical parameters with expression of various proteins in ESCC by immunohistochemistry . Despite aggressive attempts at identifying tumor markers specific to esophageal cancer, no definitive marker has been identified that can be used universally to monitor tumor recurrence.…”

Section: Discussionmentioning

confidence: 99%

Ethyl gallate as a novel ERK1/2 inhibitor suppresses patient‐derived esophageal tumor growth

Liu

Xie

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Ethyl gallate (EG) is a phenolic compound that is isolated from walnut kernels, euphorbia fischeriana, and galla rhois. It has been reported to exhibit antioxidant and anticancer activities. However, EG's effects on esophageal cancer have not yet been investigated.In the present study, we report that EG is a novel ERK1/2 inhibitor that suppresses esophageal cancer growth in vitro and in vivo. EG suppressed anchorage-dependent and -independent esophageal cancer cell growth. The results of in vitro kinase assays and cell-based assays indicated that EG directly binds to and inhibits ERK1 and ERK2 activities and their downstream signaling. Additionally, EG's inhibitory effect on cell growth is resistant to the re-activation of ERK1/2. EG increased G2/M phase cell cycle by reducing the expression of cyclin A2 and cyclin B1. The compound also stimulated cellular apoptosis through the activation of caspases 3 and 7 and inhibition of BCL2 expression. Notably, EG inhibited patient-derived esophageal tumor growth in an in vivo mouse model. These results indicate that EG is an ERK1/2 inhibitor that could be useful for treating esophageal cancer. K E Y W O R D S ERK1/2, esophageal cancer, ethyl gallate, patient-derived xenograft

show abstract

Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis

Cited by 42 publications

References 35 publications

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

Ethyl gallate as a novel ERK1/2 inhibitor suppresses patient‐derived esophageal tumor growth

Contact Info

Product

Resources

About